AM3 inhibits LPS-induced iNOS expression in mice

We have analyzed the effect of a patented glycoconjugate of natural origin, AM3 (commercially available under the name Inmunoferon®) in the expression of iNOS induced by administration of LPS in mice. We have observed that oral treatment with the drug daily for 6 days reduced the levels of expressio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International immunopharmacology 2005-07, Vol.5 (7), p.1165-1170
Hauptverfasser: Majano, Pedro, Alonso-Lebrero, José Luis, Janczyk, Agnieszka, Martín-Vichez, Samuel, Molina-Jiménez, Francisca, Brieva, Aurora, Pivel, Juan Pablo, González, Salvador, López-Cabrera, Manuel, Moreno-Otero, Ricardo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1170
container_issue 7
container_start_page 1165
container_title International immunopharmacology
container_volume 5
creator Majano, Pedro
Alonso-Lebrero, José Luis
Janczyk, Agnieszka
Martín-Vichez, Samuel
Molina-Jiménez, Francisca
Brieva, Aurora
Pivel, Juan Pablo
González, Salvador
López-Cabrera, Manuel
Moreno-Otero, Ricardo
description We have analyzed the effect of a patented glycoconjugate of natural origin, AM3 (commercially available under the name Inmunoferon®) in the expression of iNOS induced by administration of LPS in mice. We have observed that oral treatment with the drug daily for 6 days reduced the levels of expression of iNOS induced by an intravenous pulse of LPS. This effect was significant in the lungs and kidneys, but it was much more marked in the liver. In addition, the levels of nitric oxide in serum were clearly decreased upon treatment with AM3. Together, these results suggest that AM3 modulates the nitric oxide response and points to a possible role for AM3 in the control of the inflammatory response.
doi_str_mv 10.1016/j.intimp.2005.02.009
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67868345</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576905000524</els_id><sourcerecordid>67868345</sourcerecordid><originalsourceid>FETCH-LOGICAL-c336t-2cc9984bb2b0a0083913352582b290a232dfd40929eec42536303b22763e42603</originalsourceid><addsrcrecordid>eNqFkE1Lw0AQhhdRbK3-A5Fc9JY4-5nsRZDiF1QrVM9Lspniliapu6nov3dLC73paYbheV-Gh5BzChkFqq4XmWt716wyBiAzYBmAPiBDWuRFSnOQh3GXKk9lrvSAnISwAIh3QY_JgEpNBWd0SOD2mSeu_XCV60MyeZ2lrq3XFuvEvUxnCX6vPIbgujZCSeMsnpKjebkMeLabI_J-f_c2fkwn04en8e0ktZyrPmXWal2IqmIVlAAF15RzyWTBKqahZJzV81qAZhrRCia54sArxnLFUTAFfESutr0r332uMfSmccHiclm22K2DUXmhCi7kvyDNhdRa5xEUW9D6LgSPc7Pyrin9j6FgNkrNwmyVmo1SA8xEpTF2setfVw3W-9DOYQQud0AZbLmc-7K1Luw5VVABdPPozZbDqO3LoTfBOmyja-fR9qbu3N-f_AIPc5JT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17459997</pqid></control><display><type>article</type><title>AM3 inhibits LPS-induced iNOS expression in mice</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Majano, Pedro ; Alonso-Lebrero, José Luis ; Janczyk, Agnieszka ; Martín-Vichez, Samuel ; Molina-Jiménez, Francisca ; Brieva, Aurora ; Pivel, Juan Pablo ; González, Salvador ; López-Cabrera, Manuel ; Moreno-Otero, Ricardo</creator><creatorcontrib>Majano, Pedro ; Alonso-Lebrero, José Luis ; Janczyk, Agnieszka ; Martín-Vichez, Samuel ; Molina-Jiménez, Francisca ; Brieva, Aurora ; Pivel, Juan Pablo ; González, Salvador ; López-Cabrera, Manuel ; Moreno-Otero, Ricardo</creatorcontrib><description>We have analyzed the effect of a patented glycoconjugate of natural origin, AM3 (commercially available under the name Inmunoferon®) in the expression of iNOS induced by administration of LPS in mice. We have observed that oral treatment with the drug daily for 6 days reduced the levels of expression of iNOS induced by an intravenous pulse of LPS. This effect was significant in the lungs and kidneys, but it was much more marked in the liver. In addition, the levels of nitric oxide in serum were clearly decreased upon treatment with AM3. Together, these results suggest that AM3 modulates the nitric oxide response and points to a possible role for AM3 in the control of the inflammatory response.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2005.02.009</identifier><identifier>PMID: 15914321</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>AM3 ; Animals ; Anti-Inflammatory Agents - pharmacology ; Anti-inflammatory response ; Biological and medical sciences ; Calcium Phosphates - pharmacology ; Female ; Gene Expression - drug effects ; Glycopeptides - pharmacology ; Inmunoferon ; iNOS ; Lipopolysaccharides - antagonists &amp; inhibitors ; Male ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Nitric oxide ; Nitric Oxide - biosynthesis ; Nitric Oxide Synthase - genetics ; Nitric Oxide Synthase Type II ; Pharmacology. Drug treatments ; Rats ; Rats, Inbred Lew ; Tumor Necrosis Factor-alpha - biosynthesis</subject><ispartof>International immunopharmacology, 2005-07, Vol.5 (7), p.1165-1170</ispartof><rights>2005 Elsevier B.V.</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c336t-2cc9984bb2b0a0083913352582b290a232dfd40929eec42536303b22763e42603</citedby><cites>FETCH-LOGICAL-c336t-2cc9984bb2b0a0083913352582b290a232dfd40929eec42536303b22763e42603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.intimp.2005.02.009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16814015$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15914321$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Majano, Pedro</creatorcontrib><creatorcontrib>Alonso-Lebrero, José Luis</creatorcontrib><creatorcontrib>Janczyk, Agnieszka</creatorcontrib><creatorcontrib>Martín-Vichez, Samuel</creatorcontrib><creatorcontrib>Molina-Jiménez, Francisca</creatorcontrib><creatorcontrib>Brieva, Aurora</creatorcontrib><creatorcontrib>Pivel, Juan Pablo</creatorcontrib><creatorcontrib>González, Salvador</creatorcontrib><creatorcontrib>López-Cabrera, Manuel</creatorcontrib><creatorcontrib>Moreno-Otero, Ricardo</creatorcontrib><title>AM3 inhibits LPS-induced iNOS expression in mice</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>We have analyzed the effect of a patented glycoconjugate of natural origin, AM3 (commercially available under the name Inmunoferon®) in the expression of iNOS induced by administration of LPS in mice. We have observed that oral treatment with the drug daily for 6 days reduced the levels of expression of iNOS induced by an intravenous pulse of LPS. This effect was significant in the lungs and kidneys, but it was much more marked in the liver. In addition, the levels of nitric oxide in serum were clearly decreased upon treatment with AM3. Together, these results suggest that AM3 modulates the nitric oxide response and points to a possible role for AM3 in the control of the inflammatory response.</description><subject>AM3</subject><subject>Animals</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Anti-inflammatory response</subject><subject>Biological and medical sciences</subject><subject>Calcium Phosphates - pharmacology</subject><subject>Female</subject><subject>Gene Expression - drug effects</subject><subject>Glycopeptides - pharmacology</subject><subject>Inmunoferon</subject><subject>iNOS</subject><subject>Lipopolysaccharides - antagonists &amp; inhibitors</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - biosynthesis</subject><subject>Nitric Oxide Synthase - genetics</subject><subject>Nitric Oxide Synthase Type II</subject><subject>Pharmacology. Drug treatments</subject><subject>Rats</subject><subject>Rats, Inbred Lew</subject><subject>Tumor Necrosis Factor-alpha - biosynthesis</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1Lw0AQhhdRbK3-A5Fc9JY4-5nsRZDiF1QrVM9Lspniliapu6nov3dLC73paYbheV-Gh5BzChkFqq4XmWt716wyBiAzYBmAPiBDWuRFSnOQh3GXKk9lrvSAnISwAIh3QY_JgEpNBWd0SOD2mSeu_XCV60MyeZ2lrq3XFuvEvUxnCX6vPIbgujZCSeMsnpKjebkMeLabI_J-f_c2fkwn04en8e0ktZyrPmXWal2IqmIVlAAF15RzyWTBKqahZJzV81qAZhrRCia54sArxnLFUTAFfESutr0r332uMfSmccHiclm22K2DUXmhCi7kvyDNhdRa5xEUW9D6LgSPc7Pyrin9j6FgNkrNwmyVmo1SA8xEpTF2setfVw3W-9DOYQQud0AZbLmc-7K1Luw5VVABdPPozZbDqO3LoTfBOmyja-fR9qbu3N-f_AIPc5JT</recordid><startdate>200507</startdate><enddate>200507</enddate><creator>Majano, Pedro</creator><creator>Alonso-Lebrero, José Luis</creator><creator>Janczyk, Agnieszka</creator><creator>Martín-Vichez, Samuel</creator><creator>Molina-Jiménez, Francisca</creator><creator>Brieva, Aurora</creator><creator>Pivel, Juan Pablo</creator><creator>González, Salvador</creator><creator>López-Cabrera, Manuel</creator><creator>Moreno-Otero, Ricardo</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200507</creationdate><title>AM3 inhibits LPS-induced iNOS expression in mice</title><author>Majano, Pedro ; Alonso-Lebrero, José Luis ; Janczyk, Agnieszka ; Martín-Vichez, Samuel ; Molina-Jiménez, Francisca ; Brieva, Aurora ; Pivel, Juan Pablo ; González, Salvador ; López-Cabrera, Manuel ; Moreno-Otero, Ricardo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c336t-2cc9984bb2b0a0083913352582b290a232dfd40929eec42536303b22763e42603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>AM3</topic><topic>Animals</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Anti-inflammatory response</topic><topic>Biological and medical sciences</topic><topic>Calcium Phosphates - pharmacology</topic><topic>Female</topic><topic>Gene Expression - drug effects</topic><topic>Glycopeptides - pharmacology</topic><topic>Inmunoferon</topic><topic>iNOS</topic><topic>Lipopolysaccharides - antagonists &amp; inhibitors</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - biosynthesis</topic><topic>Nitric Oxide Synthase - genetics</topic><topic>Nitric Oxide Synthase Type II</topic><topic>Pharmacology. Drug treatments</topic><topic>Rats</topic><topic>Rats, Inbred Lew</topic><topic>Tumor Necrosis Factor-alpha - biosynthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Majano, Pedro</creatorcontrib><creatorcontrib>Alonso-Lebrero, José Luis</creatorcontrib><creatorcontrib>Janczyk, Agnieszka</creatorcontrib><creatorcontrib>Martín-Vichez, Samuel</creatorcontrib><creatorcontrib>Molina-Jiménez, Francisca</creatorcontrib><creatorcontrib>Brieva, Aurora</creatorcontrib><creatorcontrib>Pivel, Juan Pablo</creatorcontrib><creatorcontrib>González, Salvador</creatorcontrib><creatorcontrib>López-Cabrera, Manuel</creatorcontrib><creatorcontrib>Moreno-Otero, Ricardo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Majano, Pedro</au><au>Alonso-Lebrero, José Luis</au><au>Janczyk, Agnieszka</au><au>Martín-Vichez, Samuel</au><au>Molina-Jiménez, Francisca</au><au>Brieva, Aurora</au><au>Pivel, Juan Pablo</au><au>González, Salvador</au><au>López-Cabrera, Manuel</au><au>Moreno-Otero, Ricardo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AM3 inhibits LPS-induced iNOS expression in mice</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2005-07</date><risdate>2005</risdate><volume>5</volume><issue>7</issue><spage>1165</spage><epage>1170</epage><pages>1165-1170</pages><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>We have analyzed the effect of a patented glycoconjugate of natural origin, AM3 (commercially available under the name Inmunoferon®) in the expression of iNOS induced by administration of LPS in mice. We have observed that oral treatment with the drug daily for 6 days reduced the levels of expression of iNOS induced by an intravenous pulse of LPS. This effect was significant in the lungs and kidneys, but it was much more marked in the liver. In addition, the levels of nitric oxide in serum were clearly decreased upon treatment with AM3. Together, these results suggest that AM3 modulates the nitric oxide response and points to a possible role for AM3 in the control of the inflammatory response.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>15914321</pmid><doi>10.1016/j.intimp.2005.02.009</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1567-5769
ispartof International immunopharmacology, 2005-07, Vol.5 (7), p.1165-1170
issn 1567-5769
1878-1705
language eng
recordid cdi_proquest_miscellaneous_67868345
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects AM3
Animals
Anti-Inflammatory Agents - pharmacology
Anti-inflammatory response
Biological and medical sciences
Calcium Phosphates - pharmacology
Female
Gene Expression - drug effects
Glycopeptides - pharmacology
Inmunoferon
iNOS
Lipopolysaccharides - antagonists & inhibitors
Male
Medical sciences
Mice
Mice, Inbred BALB C
Nitric oxide
Nitric Oxide - biosynthesis
Nitric Oxide Synthase - genetics
Nitric Oxide Synthase Type II
Pharmacology. Drug treatments
Rats
Rats, Inbred Lew
Tumor Necrosis Factor-alpha - biosynthesis
title AM3 inhibits LPS-induced iNOS expression in mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T09%3A07%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AM3%20inhibits%20LPS-induced%20iNOS%20expression%20in%20mice&rft.jtitle=International%20immunopharmacology&rft.au=Majano,%20Pedro&rft.date=2005-07&rft.volume=5&rft.issue=7&rft.spage=1165&rft.epage=1170&rft.pages=1165-1170&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2005.02.009&rft_dat=%3Cproquest_cross%3E67868345%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17459997&rft_id=info:pmid/15914321&rft_els_id=S1567576905000524&rfr_iscdi=true